Ber Oomen | Executive Secretary and Treasurer
‎European Specialist Nurses Organisations

Ber Oomen, Executive Secretary and Treasurer, ‎European Specialist Nurses Organisations

In the role of Executive Secretary of ESNO, he beside the association managment also promoter and supporter of the role and position of Specialist Nurses in European context. So far most of European members have specialised nurses and some imbedded in national legislation as specialist, but all have their definition and description. It is key that there is a common understanding of this title for cross border and interdisciplinary communication and health safety. His role is also assisting in streamlining the process and Continuing Professional Development programs such as the Common Training Framework with Accreditation within the ESNO and advocate the profession in health programs in Brussels. One of his activities is leading ESNO focus group of the European nursing guideline on biosimilar.'


Biosimilars Day 1 - Tuesday 31st October 2017 @ 09:50

International stakeholders panel discussion: What does it take to get biosimilars moving in a country?

  • Consisting of industry panellists, physicians, pharmacists, patient advocacy groups, payers, regulators and health authorities, the 360° Perspective Panel allows the whole industry to come together to discuss and debate the sector’s most pertinent topics of the day.
  • With no guarantee that physicians will prescribe biosimilars interchangeably with reference products, what more does the industry need to do to encourage biosimilar uptake within healthcare?
  • What can we learn from gainsharing practices? Carrot & stick models, which works better?
  • How influential are payers in the speed in which biosimilars are taken up in healthcare systems?
  • How does the industry envisage overcoming the challenge that patient communities are generally unaware of this new, yet important, category of medicines?

Biosimilars Day 1 - Tuesday 31st October 2017 @ 14:30

What is the role of specialised nurses in the decision-making process of a patient’s treatment of in the hospital treatment regime?

  • Change management – how to build confidence with the patient?
  • Why is a switch initiated and what does this mean?
  • How will a nurse interact with the patient?
  • Examples of switches being made in key therapeutic areas such as Rheumatology, Oncology, Inflammatory Bowel Disease and other autoimmune diseases and Endocrinology

back to speakers